<SEC-DOCUMENT>0001213900-26-060784.txt : 20260526
<SEC-HEADER>0001213900-26-060784.hdr.sgml : 20260526
<ACCEPTANCE-DATETIME>20260526080237
ACCESSION NUMBER:		0001213900-26-060784
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260526
DATE AS OF CHANGE:		20260526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-292303
		FILM NUMBER:		261015988

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea029212303-424b3_kazia.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-292303 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(to Prospectus dated December 23, 2025) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10,700,211 American Depositary Shares representing
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,350,105,500 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ordinary Shares </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea029212303_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kazia Therapeutics Limited</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement is being filed to update and supplement
the information contained in the prospectus dated December 23, 2025 (the &ldquo;Prospectus&rdquo;), which forms a part of our Registration
Statement on Form F-1 (Registration No. 333-292303), with the information contained in our current report on Form 6-K, furnished to the
Securities and Exchange Commission on May 26, 2026 (the &ldquo;May 26, 2026 Form 6-K&rdquo;). Accordingly, we have attached the May 26,
2026 Form 6-K to this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement updates and supplements the information
in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including
any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any
inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ADSs are listed on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;)
under the symbol &ldquo;KZIA.&rdquo; On May 22, 2026, the last reported sale price of the ADSs on Nasdaq was $13.66 per ADS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk. See
&ldquo;Risk Factors&rdquo; beginning on page 9 of the Prospectus and the &ldquo;Risk Factors&rdquo; in &ldquo;Item 3. Key Information-D.
Risk Factors&rdquo; of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in
any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus
supplement. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement is May
26, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of May 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 000-29962</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kazia Therapeutics Limited. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three International Towers Level 24 300 Barangaroo
Avenue Sydney NSW 2000 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS FORM 6-K REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Press Release</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 26, 2026, Kazia Therapeutics Limited (the &ldquo;Company&rdquo;)
issued a press release titled &ldquo;Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer&rdquo;. A
copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Incorporation by Reference</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company hereby incorporates by reference the information contained
herein, including 99.1, except for the quotes of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into
the Company&rsquo;s registration statements on Form F-3 (File Nos. <A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000119312523296811/d866423df3.htm">333-276091</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000119312524213396/d867638df3.htm">333-281937</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000121390026029366/ea0281732-f3_kazia.htm">333-294392</A>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%"><B>Exhibit</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 90%"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>99.1</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_001"><U>Press Release dated May 26, 2026.</U></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>Kazia Therapeutics Limited.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">/s/ John Friend</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: </TD>
    <TD>John Friend</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date: May 26, 2026</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><A NAME="a_001"></A><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kazia Therapeutics Expands Ongoing Phase 1b
Trial of Paxalisib in Advanced Breast Cancer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Planned Enrollment to Increase from 12 to 36
Patients Following Continued Encouraging Safety and Tolerability Data</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>SYDNEY, Australia, May 26, 2026 &ndash;</B>
<U>Kazia Therapeutics</U> Limited (NASDAQ: KZIA) (&ldquo;Kazia&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage oncology company
advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced plans to expand its ongoing
Phase 1b clinical trial evaluating lead asset <U>paxalisib</U> in combination with standard-of-care therapies in patients with advanced
triple negative breast cancer (&ldquo;TNBC&rdquo;). Based on continued encouraging safety, tolerability and clinical activity data observed
to date, planned enrollment has increased from 12 to 36 patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The expansion is intended to further evaluate
the safety, tolerability, dose optimization and preliminary efficacy of the paxalisib-based combination regimen with pembrolizumab and
chemotherapy. The expanded dataset is expected to provide a more meaningful assessment of objective response rate (&ldquo;ORR&rdquo;),
progression-free survival (&ldquo;PFS&rdquo;) and translational biomarkers. Additional clinical trial updates are anticipated throughout
2026 and into 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;We remain encouraged by the safety and tolerability data observed to date, and expanding enrollment allows us to generate a broader
clinical and translational dataset as we advance paxalisib in difficult-to-treat advanced breast cancer, such as TNBC,&rdquo; said Dr.
John Friend, CEO, Kazia Therapeutics. &ldquo;Paxalisib&rsquo;s mechanism, modulating key resistance and immune-related pathways, addresses
the very reasons that current therapies fail, and we believe it holds meaningful potential for an underserved patient population. While
we planned to present scientific progress at ASCO 2026, we made the decision to withdraw our abstracts solely to protect our intellectual
property position ahead of anticipated filings. The withdrawal was not related to any safety or clinical concerns. We expect to share
additional clinical and translational updates in the coming months.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Phase 1b study is evaluating paxalisib in
combination with established breast cancer regimens across multiple dose cohorts. The trial expansion is supported by a recently published
<U>preclinical study</U> in <I>Molecular Cancer Therapeutics</I>, a journal of the American Association for Cancer Research (&ldquo;AACR&rdquo;),
demonstrating that dual PI3K/mTOR inhibition with paxalisib altered tumor cell state and immune signaling in preclinical TNBC models.
TNBC accounts for approximately 15 to 20 percent of all breast cancer diagnoses and is associated with poorer outcomes relative to other
breast cancer subtypes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About Kazia Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Kazia Therapeutics (NASDAQ: KZIA) is an oncology-focused
drug development company, based in Sydney, Australia. The Company&rsquo;s lead asset, paxalisib, is an investigational brain penetrant
inhibitor of the PI3K/Akt /mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016,
paxalisib is or has been the subject of 10 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024,
and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Other clinical trials involving paxalisib are
ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several
of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food
and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted
FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Additionally, paxalisib was granted Rare Pediatric
Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid
/ rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which
was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class
intracellular&nbsp;PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression,
as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become
resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. For more information,
please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Forward Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;future,&rdquo; &ldquo;forward,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo;
&ldquo;believe,&rdquo; &ldquo;potential,&rdquo; or other similar words. Any statement describing Kazia&rsquo;s future plans,
strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also
forward-looking statements, including, but not limited to, statements regarding: the planned expansion of the Phase 1b clinical
trial of paxalisib in advanced TNBC; the anticipated increase in enrollment from 12 to 36 patients; expectations regarding the
safety, tolerability, dose optimization and preliminary efficacy of paxalisib in combination with pembrolizumab and chemotherapy;
the potential of paxalisib to treat advanced breast cancer, including TNBC; expectations regarding objective response rate,
progression-free survival and translational biomarkers; anticipated timing of clinical trial updates throughout 2026 and into 2027;
the timing and content of future public disclosures regarding the Company&rsquo;s clinical programs;&nbsp;the Company&rsquo;s decisions
regarding the timing and manner of scientific presentations and publications, including the withdrawal of abstracts from scientific
conferences for intellectual property-related reasons;&nbsp;and statements regarding the potential therapeutic benefit of paxalisib
to modulate key resistance and immune-related pathways in difficult-to-treat breast cancer populations. Such statements are based on
Kazia&rsquo;s current expectations and projections about future events and future trends affecting its business and are subject to certain
risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking
statements, including risks and uncertainties associated with: the development of early-stage therapeutic programs; the conduct of
clinical trials, including the ability to enroll patients and achieve anticipated enrollment targets; the preliminary nature of data
from a small, open-label clinical study, which may not be predictive of later-stage clinical results; risks related to regulatory
approvals; risks related to Kazia&rsquo;s reliance on third-party collaborators and clinical trial sites;&nbsp;risks related to the
Company&rsquo;s ability to obtain, maintain and protect its intellectual property, including decisions regarding the timing and manner of
scientific disclosures;&nbsp;risks related to the impact of global economic conditions; and risks related to Kazia&rsquo;s ability to
maintain compliance with the applicable NASDAQ continued listing requirements and standards. These and other risks and
uncertainties are described more fully in Kazia&rsquo;s Annual Report on Form 20-F filed with the SEC, and in subsequent filings with the
United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should
not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michaela Fawcett</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KCSA Strategic Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">mfawcett@kcsa.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ea029212303_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029212303_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ ,$# 2(  A$! Q$!_\0
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M0?.";QM SC -OX;_  ,\ ?"7P1<?"7QCKOAS7+GQ1K']M7FD^(;31L7X./\
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M9&/ZUQ7B_P 6Z1X+\,:]XPUZZM]&T#PUI&K:QK&IW0 6RT_15>21F4<8(1B
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M7BU@%37)=145%:1ORI:1Z1LNFV]U<]?B^ '_  Q=\6?B3^UYXP\?:UKGA?\
MXFE\/#VE7>=3OCKN"NC8XZ$ ]L'!!]/KCP'XV^"_[8WP@T_XFCPK<ZEI^EWF
MIB\TG5K,_P!I6&J:$>=%]^ ,#U[C.:]?UZ;PM\6O@5<S>,=!_M+PKKOAE;[5
M] N[0'.F'1CKS+MZC "G.<'/J#7QC_P3R_:+\#_$VY\8_"3P1\,Q\/\ P]X#
M_P!-T@D_VD+X<:"23QP/RZ\XKRL/]<RG.'@GJDW=;VU=^ZZ=/4]7,OJ?'W"/
MU]QC%\BE=I)_#S+HG>_GY==?1OV:_P!J35?B-X[U?P#_ ,(L-#T?3-)U(:/=
MVW L#H9"XUO)ZG.%]6..]?HK:[6B^TK-]I+<<= ?I[8S]WU^E?FWIW[17A;1
M_P!I6Y^$FD_#G3+:YNM8.C:OXBM+,Z;J0./J,@?4>F:_2"R_<VHAZBUQQV]<
M_C^'ZU[^<)7CB[=KQMOJKMV\^Z['P?!=?$K"YG@WF2GR-J-TFTE=63:=M$D[
M/4_A._X.+-1N(?\ @HMX?S-:C1[3X*?#&\U<#_D) #7/$ 4\=/E ..O)],5R
M_P :OCA\:/\ @M%^V1\,/@!\,;^Z\)?";0=(TVS\-VE[?Z0VFZ#I>B:/H+>.
M_&FN:(Q)\0 %CM&=J#"(%0*HZ#_@XFF@/_!27P_!Y((/P4^#GVNUNN!?K_PF
MOB#  &>@P"00">>,X"_M]_LC_$;_ ();?M(_"?\ :]_9RN+G1/AOXH/ACQ-X
M;U?_ )AGA+Q2-'T%=>\%Z[R1_P ([XLQ]?7GBO=T^IY5MS.+MMVU_-=]#T,3
MS>]N]T[7W][_ ()_9-^S#^S?\-/V4?@OX'^!_P +;#[+X7\,6>FV7VL<ZEXL
MU,'&MZSKAQDEOO$?P?=R< M]4S&;RB8,>?P?T/KQCI_7FO@?]@G]M'P!^W+\
M!] ^+7A">UT[7S9_8?'GA+[7_P 3/PGXG(Y#=0<\^F>F/7[.\1ZE8:5H6NZI
MJM];:9IVFV;7EYJMS<G;8Z;M+%B0#MX4X+'#%@,DXKXK$X?%_7.RNUY.\M.R
M[+[OE]-E[2P;>BLK]NC[_C\O,_G_ /\ @X6_;(F^"?[-&F_L_>%-6(\<_M%:
MM)8:RME>@:AHGPOT9U?7V9,9+>*BA\+H=W DER#NR?Q:_P""*W[37C#]B[]M
M>U^ /QC@U'P5X0_: TCPOH^KZ3J]E_9QT_Q[KH*_"G7%SR&\6JS+D8P">Q(/
MR1^V]^U1JO[8W[</C#XX0>%;GXD?#_X<^)=+T7P'X3M/[9_T_P ">!M:/M_S
M-G7UQUJO^V]^TYX__:Z^+^@?'Z?X$:W\ ?%'@WP?X7T47=IH^LG3,Z'K6="U
MG^W?K_\ KY)K[7#89/!O!M*[3;>BU:7?5M^3Z:GR6)Q#6,^MJ]D[6UZ.VVVA
M_H_::+W_ $C[;.,_:CM( Z8! 'H#\N,?AGC''?$WP%X)^)OA76? WC[P]IOB
M7PAKUD;'Q'H&L#.FW^FG/W@"N1G&,%21D<8R?B[_ ()D_M4Z?^V!^RE\-/C"
M;P-XINM(_P"$:^(VE$KG3O'NA!DU]U!(/_%5;QXE8C)Q(!_>%?6?Q?\ 'GA3
MX8>$O&'Q%\;ZK:Z)X/\ !O@_5?%'B35KKI8Z9H>6)'7.22>>2<GW/R7U;ZMC
M/JG=]NK:6_:[6^][['TOUE8K!W\G]R5[]^G;H?R;?\%V-)_8\_9E\+>!_P!G
MOX+_  <\ >&?BO\ %&\'BCQ=JOA^S_XFOA+P%H2@D:,"!M;Q6205!;&,[LDJ
M/UA_X(D_L9S_ +,?[)>G^,?'&E7.F?%?X[_V7\0?$OVL?\3+0O"_(\"Z)GD\
M>'.N/ISR*_EW\.?$+P#^W?\ \%,(/C%^U-XWTSP#\,-3\1ZIXGU>Z\17NT?\
M('H6M?\ %">"M$(!(&>X!P.0"1BO[C_@-^U_^R_^T'?ZEX.^!/Q:\(^-=0\,
M:1F]\/Z0238Z9@#D84#@#';OU!)^DS+ZWA,$L&^J3;VZ7WT[[/HD>#EOU3%8
MSJK7ZM:IN^_H?77DP?Z/_G_'\?U]_P"$[]H.[G@_X.&Y[<=+G]H_X7XSZ#1,
M<<=/_K5_=Q_RZ#Z'_P!"%?P<?'[G_@X2N.+G[/\ \-(?"_['BS)&3HN@=_TQ
M@?RKR<D35V^B?3Y_H>QF7V?^W?\ (_O%BABW&:7[WVCY2<XW;2!G\>>>,5QO
MC_Q?I'@GPEKWB[Q%JMMHGACPS8ZIK7B/5KHG;8:7HWSLP'^UM!R?08/)SULW
M^J_Y=NG;_/Y^]?SN_P#!P3^V(/@;^RW:_ /PM>C_ (3K]HNZ;1+O%Y_Q,K#X
M7Z(5.OZT.@.2!U&>OJ:Y\,OK.+LMHM)_)I?AR_?8WQ.(^JX17NVXV_KUV/Y9
M_P!K[X[?$[]L3X]?';]KO1+/5&\,>%?%^DKH^L:7>:Q_9W@7PN-9 \"LVT*,
MG^PLD*H7)X4<"O[K/^"8O[5%G^V#^R5\,/B_)>VMUXI.CCPS\2;2 $WUEXYT
M)U65&QGGRV8J#U)R"P5@/XA/V=?VF_$?P"_95^-_[-O_  RA=>/]/_:+M-4L
M_$GC?5='UH:G8Z7H8(T+^Q ."/">3XH .1G!Z@5]W_\ ! +]K36_@!^TMJ'[
M+/C*]N=&\,?'8'[':^(!_9VG:!\3]"T3_B1A1U)\6XZ#KTYKZ#,<,L3@U;3D
M2M9ZM16JZO1*VM[V3['S.78F7US5O5];VU>F^G7N?W945G8OO^>-M17R_LEW
M7_@2/LO:+L_P/S3_ &BOBI\,O@Q\6="U35? UMK7C+7$2[M=4%J'_LW344*V
ML;AD,48%21U(-;G[8'C#0M'_ &?;?XMS?#*U^)%SI=II=[X<TGQ#H_\ :7V$
MZZ!U'4<$=<$#&3C&?=/C?\-_ GB)9?&'B?PXNN3>$+0ZY9M<8"L=&WR-I/&>
M'8EB<G+,>3G-?/?[,?[2$'[0ESXP\ >(_ &FZ9H^F:.!]D^V#4M-O]+/']C<
M\$\\^W8\5[&8X?\ M3*/]DMS*U[[W36O>VE[V_0_/.%,Q_U6XX?USX)-VMI%
MW=NC4?M.WRUW.X_9+^,-_P#'GX$>%_%7BKPY;>$M7U0:GHUYX>_YAO/'_$C'
M0 ]/4_,/2N(F_8/^$FI>+;CQ']NU(6'VS[;>:3S_ &9?_G_3->+?M$_LQ?M)
M^*OCO\/]<^#OCFW\%?"_0?\ A%S_ &5:7G]G:;H7]A\ZYC0QUXZ#Z?CL:Q\<
MOVFM'_;-M_A5I7@#4M3^$]U=Z997F;/_ )A7]BY_X33^W.HQXCQW[8.>M?,9
M9Q%F^4K-,'%M+1)QNDU9+1JW;H_O/TWB/@SAKBS%K'-PNWS>\XV3>MKMVZGU
M?^T?\3I_@9\#/%/B3P=H?_"2:SX8TC3#H^DV@_M+/8'J>@P.>H'8$ >,_L3^
M-])^)'P6UCXJ3_#JV^'_ (AN[S5/^$OL[31_[-^WG!.._.,G'H#QWKS;X/?L
MX?M"Z#^TWXY^(WQ3\?\ ]I_"_5+S5?M>DW=Y_:6F:_I>N_\ ("T7^PC_ ,B_
M_P (GC(/3TKU_P#:A_:$A_9[L/"_ASP?X(M;JWU\ZI># QI@&3_;@(R3G!Y/
M0]0!1EN&S;-,W6-EHDTW?M>\K7\KMZG/Q%F.3\+<-2R:G).\7%.#3O>+BOA>
MW7^D<S\!_C-\,OC+\6M9ALOAS;Z;XOM;/4[RS\5W=F/[2O\ 2\XR,=.H!R<#
M QCG/Z0:,<6P)_SPM?-WP"\!^!X=&T[Q_P"&_!VF^&M8\8Z/]MO1: 9/]/R]
M_7GZ@.?)X]O_ $&OIN(L1AFW'";)173625I:)O2ZTV]#X+@S+?JN5RQMM9.3
MLUK9M[JU[VDNY^,O[<__  2,^&'[;W[0&C?&_P 7_$'Q9X6UGP_X:\+^"K32
MM(M5.FMI>@ZT=<))&!DMK3 ] &!'!''WS\;/V=/AG^T5\$?$'P)^*>E'4_!^
MO^'=+T8B[M,ZE8:EH?&AZT,CCQ",[^#DD8'4"NP^(WCW7/"GB_P-HECH?]I6
MWC'5QHQO#=%?L'<G!''7)ZXKD;SX[Z3INH:SHD]N/M.E^/-*\$_9?M@W7XUS
M)&LYP"1D^IZ^]8OZVUEBN[>717Z]MNOIW1[$LQPF%DU)7NW>ZZW=]+>?KL?"
MO[!O_!)CP1^P+\1=?\=?#/XS?$KQ#I'B#1=2T;6O WB0I_PC>N$_\@36"49U
M+)SN*ED)X5VY-?HO\>?A7-\;?@MX_P#A-%XJU'PV/B'X<U31KKQ#H%T/[4CT
MW7%<,VAMD[248KD;?E)Y97K!T?XM3ZGX\\0>#[?2K86^@WFEV5Y>?;#W'7'7
M(.3C [@UB_#WXZ_\)MKT&A_V+!]GNAJM[=:K:7BZBL?]A:QM']M!0!H(S\P$
MF_#'*X 4 Q&&Q=[W5[[_ #O_ %Z_(%Q'E5_J>J\TGMIU2_$^3_V"O^"4?P"_
M8/\ ^$WOO#=S<_$C6?'1TNSO=5\;:1HO^@:7H0X71AM)"D,&."#PO."PKZN_
M:)_91^#/[0OP>\<_!?Q9X6TVU\.^.M'-C=ZIH^E+IVIZ)N"M_;6CZUY8*-'C
M"A)""&RV[C'1Z/\ 'C1M>LOB/<0V5S;S_#JZU-2+H8%]IJY)9<DXW9P02<;5
MP>23YQ#^T@/^$$\0>*9_#MM;0:9_PB]G]C_MC^TM-U >.2,_\3WK@,5SV&1W
M-;)8R][M/1/5I:6MUMI_GN&)SG*+;7LNB^7;T^\\>_X)Y_\ !.OPK_P3]T;Q
M_P"%?!GQ'\6>-?#_ (SOM+UK^R?$'_(.LM34,3K"9XW<;2>R[NA (]Q_;'_9
M8TG]K[X&>(?@3J_C'Q7X0T;QC>:9_P ))K'A\XU*_P!*T'6@6T<G P,]<]@2
M3Z>@:/\ $V>6Z\'V-[;BVN?%%WJMD/[*O!J(SH>B@\G!(RW7CKS@GKR\WQRU
M2?PQX(\4Z)X<&I_\)EK \-7=U=WG]F_V?J?]M'00<=OFS@CC(XR1BL?J^+^M
M)Z:+1NV^^^]OZ08;.LIM:SUWT=NVUOZV['X?S?\ !MG\ "! /C%\2/LW_/I_
M8^<_EW_'^=?;_P"P5_P2$^%?[!?Q/\8?%3P?X_\ $WC76/&7@]?!EYI7B"S&
MFZ;_ &8K @<$]<8(]#CUQ^@'B3XRZ?H,OC^:]L+@?\(;_P (R;O &==U37O^
M0'HPXX.3\Q'7//4"G7GQ/\5:#X(U#Q5KG@@6UQ:_\>>DVEX.^>?IUP?RKHQ.
M)QF*M];=[:+Y;?=HS!9CE.%DK)WO=63OJ_)>?<^B(A;D6]O_ ,^H_'N/\_CS
MGI^-WC;_ ((\_"OQU^W!;_MOWOQ%\6VWB]?'7ACQI_PB?V,?V6-4T'H#GD9[
M'!&T')!P#^L_A#73K&AZ??S-;7,]S9"\^TVEV-27V(.,C@].G&,9KKY88LDP
MP@S8R !^I)['/I]#7C>WQ6%>EK.ZT[._^>VI],OJF*BFM=FO6R?SZ%&:(36V
MW-QD#[)C[)@XSC('/ Z ]NG %?B]^UU_P1S^&'[8G[2.G_M"_%OXC>/?L^E#
MPQ::3\/M)(&E_P!EZ&23HY^IRQ/KDGI7[<R^=Y9Z9[X_3/MZ_P#ZJ@_>_P"=
MU;X?$O"W:W:?XZL,1AOK22Z*VG33;R/'-.^$_P /]&T^VTS3/!'A*U%K:+8V
M6?#>C:@+#3=%("J=P!)9F50.NX[<9P#^3'[47_!%OX2?'?\ :,MOVI_#OCGQ
M9\)O'.F'PQK(TGP19@::WBC0>?[9QQEMHR=H X)&!Q7[G^6/4CZ__JI_E0^G
MZ'_"L:&8XN[O?6_5VMMUTVMK;KZC^J82-O=2VZ);?)' _P!F:M_T%M2_S^-%
M>C45I[6??\_\S7DCV_%G#:C%!>27\,W^E6]L,W5KR1R.#SC.>IZ$CJ1S7R1\
M<OACKFC_  P\40_ C0]-\-^*-4O-*^UW?AX?V;J5]I0[@@<$YYYQQP/O&OM^
M.W@\Z[E\M?,=4#/SD@1Y]<=1Z5%-86;C+VT3<XY0?T^E:83$/#XG1-II-K;2
MRNM[=3PLSR/"XEN5N66GO=;O9W2OH_,_+3P'\0_BW^SW^SK<>(?BW876N>(+
M3Q']C\-^']6N_P#B9#2\\ GU/)Q@],D#*Y[#3?VOQ>? W4/B[/X5NK;4=+U?
M^Q/[)W-C^T\Y'_$ZSM_X1[KSC/&"<5]R^)O O@_Q1H]SHOB'P]INK:7*6$EE
M>0^9$P&<?Q!Q]0P)[UD:'\(?AEIWA@^"[+P3H%OX4Y']A1V8_L__ +\LQ_\
M0J]]8C)?JS4LJ3DY-MWBE9M.VMV^[;=VV]E8^!>4<1+-5A(YZU@&G:BE5Y]+
MK5Z+MUZ;GP#K'Q2^*G[2W[,VKZ]\,K"XT3QC<ZN5NK7[7\U\-#(+#0CZ-M4D
M8[ Y/&/7_P!G;X3^,=1^%6C:3\<;"VUO6--O#>6-KXAQJ6HV&F<%03U!;MP>
MAXY&?KSPA\/?!/@W3VTGPOX;TS1-.%ZTPM+*%DC\WS0N_P"=W8G!Q@MCVS78
MM;0 D")0/Q^OK7'4QE*E>.&I.GH]^79I::/L['OY?PE4Q?O9AF-7$).Z5F^[
M7Q-_R_BS!T*SATVV%O HMUP?LMJ3C QQCJ3DXYXP/P%=%#+#-YX!Z'!)'IG/
M^'_Z^;2P0D F-?R]ZC\M/[HKYUO5^K?XL^UPN&CAHJ$=8JR26VENFVR[' >(
MO!VGZ[J?A_6[R#]_X6O-3UJQ&<XU+&!CGH0,<]?J*X#4O@GX6U(ZOY\/VF?5
M/%^E^,S=$9_XFVAE=O.>, -P.N[VKZ!>WA(),:YZ]_IZT1V\*@$1J,^WO74L
M;75DI:*UOEK;T,<5E>%Q*YG&VMGHM][G@^C_  EL=-\9ZQXX@U74OM&O_P#'
MYI/_ ##/?WY_G^N3HWP*\->&)9Y]+6ZMKZ[TK5-#N[JTN6TXW^G:TS98C!4:
M^"JE).%S@E@2 ?HBYMH& +1*<G'3VJ=E4$@ ?E[5CB,=B$U[U]5U?J<JR/!?
MRZ][+\]SYCT/]G_PUX??48M*@N=.M[KPT?#-T%N\G4N"?[9UD<;V(!( YX_+
MI=6^#GA74O __"NXK.#3-'-GI=G9W.FA%U)&T<J$U4D  NIP.68[F/)#*![M
M3OL\/_/-?U_QK;Z_B+?%LK]>WJ']B8/7W=_)?Y'S9J7P3L-3TO1]*GU76_[0
MT"\-[H_B&TO#INIV'^>GKV]*Z"'X0^&_^$=\+^&X+(?8/!NL:3K>CBZY(U31
M"=I([ G//3@^A->Y$G)Y[G^9_P 3^=5KB-&3+*"<@9]C6/\ :N(O:_7OYV#^
MP\'_ "_@CQ75_A-X<UFY\7&^MS<6_C.STK^V!W']A#_B1C1<9 *\@X.,C&>0
M*SX/A--I_AVYT.#Q?XN!U%B+O5KW5CJ&I6&F;1_Q)T)'(PQ7< 0>1D@<_07V
M2W_YY+^O^-'V2W_YY+^O^-=?UB36M]5^GJ:?V3AOY5_X"O\ (\T\">!=/\!^
M&-.\*Z']J.GZ:#AKJZ+:AST)8# SV!..N.<5Z3@8\WMCK[=/_K>G?WJ7RTV8
MVC&,XYZXSFF5@W?^OZ[G9A</'#JRLU;;R>Y+O'O^G^-&\>A_3_&GT4CI&;QZ
E']/\:B\V'U_4_P"-%/P/,SC_ #C/\Z ';QZ']/\ &BGT4 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
